News
The mRNA therapeutics field is rapidly evolving beyond vaccines to include treatments for cancer, genetic disorders and in vivo cell therapies, bringing with it diverse production challenges. As the ...
Transcend Therapeutics announced that the FDA has granted breakthrough therapy designation to TSND-201 to treat PTSD.
Achieving good oral bioavailability for targeted protein degraders (TPDs) is vital in providing a patient-friendly way to ...
The US dominates overall sales, yet GlobalData predicts that China is shaping up to be a formidable presence in the cell therapy space.
Amid new regulations, changes in tariffs, supply chain disruptions, we look at how CDMOs can remain at the forefront of ...
Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around data quality.
Zentiva Group has entered a licence and supply agreement with Lupin for the commercialisation of latter’s biosimilar Certolizumab Pegol.
Merck has entered a definitive agreement to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn.
Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...
Niagen has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital to treat Parkinson's disease.
A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.
Global funding cuts, including those made by the Trump administration, are set to increase cases of HIV in Africa, research suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results